SCHEMBL4008943

SCHEMBL4008943

O=C(O)C(Cl)(Oc1cccc(C(F)(F)F)c1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 4/20 0.52
▸ PPARA Q07869 1/20 0.50
▸ MRGPRX4 Q96LA9 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ HTT P42858 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ CES2 O00748 1/20 0.44
▸ NR4A2 P43354 1/20 0.43
▸ DDR1 Q08345 1/20 0.43
▸ MAPK14 Q16539 1/20 0.42
▸ MPO P05164 1/20 0.42
▸ TLR8 Q9NR97 1/20 0.42
▸ TLR7 Q9NYK1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23519064 0.81 PPARG (0.51) PPARGPPARAMRGPRX4KDM4EHTT
SCHEMBL3372794 0.78 PPARG (0.51) PPARGPPARAMRGPRX4KDM4EKMT2A
SCHEMBL11570463 0.74 KDM4E (0.50) PPARGPPARAMRGPRX4KDM4EALDH1A1
SCHEMBL11848431 0.74 PPARG (0.54) PPARGPPARAMRGPRX4KDM4EHTT
SCHEMBL7823689 0.73 PPARG (0.47) PPARGPPARAMRGPRX4KDM4EHTT
SCHEMBL11527555 0.73 KIF11 (0.51) PPARGPPARAKDM4EMAPTCES2
Hydrochloric Acid SCHEMBL11848416 0.72 PPARG (0.52) PPARGPPARAMRGPRX4KDM4EHTT
SCHEMBL1124259 0.72 PRSS1 (0.52) PPARGPPARAMRGPRX4KDM4EHTT
SCHEMBL9494172 0.72 PRSS1 (0.67) PPARGPPARAMRGPRX4KMT2AALDH1A1
SCHEMBL10566944 0.72 KDM4E (0.48) PPARGPPARAMRGPRX4KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105143172-B DCC-mediated coupling for lipid lowering amide production 西玛贝医药公司 2016-12-14 — — CN disclosed
EP-2775835-A1 METHODS FOR TREATING GOUT IN PATIENT SUBPOPULATIONS METABOLEX, INC. (US) 2014-09-17 — — EP disclosed
WO-2013066352-A1 METHODS FOR TREATING GOUT IN PATIENT SUBPOPULATIONS METABOLEX, INC. (US) 2013-05-10 — — WO disclosed
EP-1343493-A4 USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA METABOLEX INC (US) 2009-06-24 — — EP disclosed
EP-1937620-A2 RESOLUTION OF ALPHA-(PHENOXY) PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES Metabolex Inc. (US) 2008-07-02 — — EP disclosed
WO-2007038277-A2 RESOLUTION OF ALPHA-(PHENOXY) PHENYLACETIC ACID DERIVATIVES WITH NAPHTHYL-ALKYLAMINES METABOLEX, INC. (US) 2007-04-05 — — WO disclosed
EP-1343493-A2 USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA METABOLEX, INC. (US) 2003-09-17 — — EP disclosed
WO-2002044113-A9 USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA METABOLEX INC (US) 2003-05-01 — — WO disclosed
WO-2002044113-A2 USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA METABOLEX, INC. (US) 2002-06-06 — — WO disclosed
Send feedback